<DOC>
	<DOCNO>NCT00979680</DOCNO>
	<brief_summary>This phase III trial include patient low rectal adenocarcinoma initially required APR , mean clinical distance tumor inferior pole levator ani 0.5 cm . Patients randomly assign receive high-dose radiation ( 45 + 18 Gy ) radiochemotherapy ( 45 Gy + 5FU continuous infusion ) . The surgical decision base tumor status surgery . All surgeon use homogenous SSR technique intersphincteric resection . The primary endpoint SSR rate .</brief_summary>
	<brief_title>Sphincter-preserving Surgery After Preoperative Treatment Ultra-low Rectal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<criteria>Adenocarcinoma ultralow rectum high risk abdominop√©rineal amputation Tumor classify EER UT2UT3 , whatever nodal status pathological confirmation rectal adenocarcinoma without evidence distant metastasis ( M0 ) , T2 T3 resectable tumor without striated sphincter involvement inferior margin tumor locate less 2 cm upper part levator ani . Age 18 year old Informed write consent T1 T4 ( proven invasion sphincter ) Diffuse metastatic syndrome ( curative intent , short expect life span ) preoperative incontinence ( non due tumor )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>sphincter preservation</keyword>
	<keyword>neoadjuvant therapy</keyword>
</DOC>